US pharmaceutical giant Pfizer opened a $1 billion plant in Singapore’s Tuas Biomedical Park on July 23. The 429,000 sq ft facility will produce active pharmaceutical ingredients (API) for cancer, pain, and antibiotic medicines, creating 250 new skilled jobs.
This state-of-the-art plant, an extension of Pfizer’s 20-year-old site in Singapore, has begun commercial manufacturing and earned a Green Mark gold certification for environmental sustainability.
Pfizer investing $1b
Mike McDermott, Pfizer’s chief global supply officer, stated it will be one of the company’s most automated plants among its over 30 global manufacturing sites.
“This expanded facility not only grows our overall manufacturing footprint but also strengthens our ability to manufacture breakthrough medicines that change patients’ lives,” he says.
